Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04801797
Title Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

acute myeloid leukemia

Therapies

Azacitidine + Venetoclax

Cytarabine + Idarubicin

Cytarabine + Daunoxome

Cytarabine + Daunorubicin

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST